Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Current Assets (2022 - 2025)

Historic Current Assets for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $490.0 million.

  • Day One Biopharmaceuticals' Current Assets fell 1566.71% to $490.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $490.0 million, marking a year-over-year decrease of 1566.71%. This contributed to the annual value of $562.3 million for FY2024, which is 4984.52% up from last year.
  • As of Q3 2025, Day One Biopharmaceuticals' Current Assets stood at $490.0 million, which was down 1566.71% from $494.4 million recorded in Q2 2025.
  • Over the past 5 years, Day One Biopharmaceuticals' Current Assets peaked at $581.0 million during Q3 2024, and registered a low of $326.0 million during Q1 2024.
  • For the 4-year period, Day One Biopharmaceuticals' Current Assets averaged around $448.3 million, with its median value being $449.8 million (2023).
  • Data for Day One Biopharmaceuticals' Current Assets shows a peak YoY increase of 5601.16% (in 2025) and a maximum YoY decrease of 1566.71% (in 2025) over the last 5 years.
  • Over the past 4 years, Day One Biopharmaceuticals' Current Assets (Quarter) stood at $347.9 million in 2022, then grew by 7.88% to $375.3 million in 2023, then skyrocketed by 49.85% to $562.3 million in 2024, then decreased by 12.87% to $490.0 million in 2025.
  • Its last three reported values are $490.0 million in Q3 2025, $494.4 million for Q2 2025, and $508.7 million during Q1 2025.